Treatment of Acquired Angioedema (AAE-C1-INH) During a Clinically Significant Acute Attack Requiring Admission or Injected Therapy
Acquired angioedema secondary to C1 esterase inhibitor deficiency (AAE-C1-INH) can produce acute attacks that are potentially life-threatening or severely disabling. When an attack meets the threshold for clinical significance, a specific evidence-based intervention is indicated.
Clinical Scenario
The patient carries a confirmed diagnosis of AAE-C1-INH and is presenting with a clinically significant acute attack — one that is either potentially life-threatening because it affects the head or neck, or causes pain or disability sufficient to prevent the patient from continuing normal activities. Clinical and risk assessment has determined that admission and injected treatment are required.
Treatment Approach (partial overview)
Acute management centres on specific injectable agents; available options include both a bradykinin-receptor–targeted agent and an intravenous C1-esterase inhibitor replacement product.
The complete protocol specifies how to choose between them, guidance on product selection (including recombinant versus plasma-derived preparations), and the full decision algorithm — all available via the link below.
References
- Patient with a diagnosis of AAE-C1-INH with a clinically significant attack that requires admission/injected treatment on clinical and risk assessment.
- A clinically significant attack as defined by i) potentially life threatening because it affects the head or neck or ii) causes pain or disability such that the patient cannot continue their normal activities.
- Icatibant.
- Intravenous C1-esterase inhibitor.
- In appropriate cases and where available, licensed recombinant products should be considered in preference to plasma-derived products in the treatment of acute attacks.
View source ↗